Norfloxacin versus trimethoprim-sulfamethoxazole in the treatment of urinary tract infections.
In a controlled, randomized trial of 133 patients with proven urinary tract infections (UTIs), significantly more pathogens were found to be susceptible to norfloxacin than to trimethoprim-sulfamethoxazole (TMP-SMZ) (p less than 0.01). Among patients with pathogens susceptible to both drugs, more of those treated with norfloxacin were cured or improved (p = 0.06). When at least one patient variable, i.e., prior history of therapy, was corrected for, this difference became significant (p = 0.03). Norfloxacin eradicated 11 of 13 infections due to Pseudomonas aeruginosa and 6 of 7 due to enterococci. Five patients treated with norfloxacin and two treated with TMP-SMZ had relapses within 6 weeks. Significantly fewer adverse experiences occurred in patients receiving norfloxacin (p less than 0.01).
Medical Affairs Division, Merck Sharp & Dohme Research Laboratories, West Point, Pa.
M L
ML
Corrado
M
M
Hesney
W E
WE
Struble
K R
KR
Brown
R H
RH
Eng
R
R
Landes
L
L
Harrison
J
J
Ryan
O T
OT
Bolding
D000328:Adult; D000368:Aged; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009643:Norfloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D009643:Norfloxacin